Tag: Covishield

Vaccination drive: Kodagu highest, Dakshina Kannada clocks lowest percentage
Coronavirus Update, COVID-19, News

Vaccination drive: Kodagu highest, Dakshina Kannada clocks lowest percentage

January 17, 2021

Tepid response in Mysuru district on inaugural day Mysuru/Bengaluru: While the hilly district of Kodagu registered the highest vaccination percentage of 84 per cent, Dakshina Kannada has clocked the lowest percentage of 34 per cent on the first day of nationwide vaccine drive launched by Prime Minister Narendra Modi on Saturday. As against 21,658 persons…

India’s vaccine wait is over
Coronavirus Update, COVID-19, News

India’s vaccine wait is over

January 3, 2021

Covishield, Covaxin approved The vaccines are 110 percent safe: Drug Controller General of India  Both vaccines to be administered in two doses Can be stored in normal refrigerator New Delhi: It is indeed a red-letter day for India today as two vaccines for COVID-19 produced by Pune-based Serum Institute’s Covishield and Bharat Biotech’s Covaxin, received…

India’s Covishield vaccine awaits approval
Coronavirus Update, COVID-19, News

India’s Covishield vaccine awaits approval

December 7, 2020

Serum Institute seeks Emergency Use Authorisation for COVID-19 vaccine Clinical trials were conducted at JSS Medical College in Mysuru in August  New Delhi: The Serum Institute of India (SII) yesterday became the country’s first company to apply to the Drugs Controller General of India (DCGI) seeking Emergency Use Authorisation (EUA) for the Oxford COVID-19 vaccine…

Covishield clinical trial begins at JSS Hospital
Coronavirus Update, COVID-19, News

Covishield clinical trial begins at JSS Hospital

August 29, 2020

Mysuru District Hospital begins to issue COVID Death Certificates Mysore/Mysuru: The much-awaited clinical trial of COVID-19 vaccine – Covishield – developed by the University of Oxford began at JSS Hospital in city this morning. Pune-based Serum Institute of India partnered with AstraZeneca to manufacture the COVID-19 vaccine candidate. The volunteers received their first doses intramuscularly…

Phase-2 human trials of COVID-19 vaccine to begin at JSS Hospital soon
Coronavirus Update, COVID-19, News

Phase-2 human trials of COVID-19 vaccine to begin at JSS Hospital soon

August 26, 2020

Mysore/Mysuru: The Phase-2 human trials of Oxford University’s COVID-19 vaccine ‘Covishield’, manufactured at the Pune-based Serum Institute of India (SII)  will begin at Mysuru’s JSS Hospital and Medical College in a couple of days. The Institute is awaiting guidelines and samples from SII.  The JSS Hospital has been shortlisted to take up the COVID-19 vaccine…

JSS Hospital shortlisted for COVID vaccine, drug trials
Coronavirus Update, COVID-19, News

JSS Hospital shortlisted for COVID vaccine, drug trials

August 3, 2020

Clinical trial to evaluate if Covishield vaccine can prevent symptomatic Coronavirus Disease 2019 (COVID-19) Mysore/Mysuru: Mysuru’s JSS Hospital and Medical College has been shortlisted by Indian Council of Medical Research (ICMR) for Serum Institute of India’s COVID-19 vaccine candidate — Covishield — trial. The clinical trial is designed to evaluate if an investigational vaccine can…

ABOUT

Mysuru’s favorite and largest circulated English evening daily has kept the citizens of Mysuru informed and entertained since 1978. Over the past 41 years, Star of Mysore has been the newspaper that Mysureans reach for every evening to know about the happenings in Mysuru city. The newspaper has feature rich articles and dedicated pages targeted at readers across the demographic spectrum of Mysuru city. With a readership of over 2,50,000 Star of Mysore has been the best connection between it’s readers and their leaders; between advertisers and customers; between Mysuru and Mysureans.

CONTACT

Academy News Papers Private Limited, Publishers, Star of Mysore & Mysuru Mithra, 15-C, Industrial ‘A’ Layout, Bannimantap, Mysuru-570015. Phone no. – 0821 249 6520

To advertise on Star of Mysore, email us at

Online Edition: [email protected]
Print Editon: [email protected]
For News/Press Release: [email protected]